The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Monopar Therapeutics Inc shares valued at $15,254 were purchased by Cittadine Andrew on Jun 20 ’24. At $0.74 per share, Cittadine Andrew acquired 20,508 shares. The insider’s holdings grew to 186,132 shares worth approximately $6.08 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Cittadine Andrew purchased 12,000 shares, netting a total of over 10,320 in proceeds. Following the buying of shares at $0.86 each, the insider now holds 165,624 shares.
Before that, Cittadine Andrew had added 12,000 shares to its account. In a trade valued at $11,176, the Chief Operating Officer bought Monopar Therapeutics Inc shares for $0.93 each. Upon closing the transaction, the insider’s holdings increased to 12,000 shares, worth approximately $4.63 million.
As published in their initiating research note from Rodman & Renshaw on October 11, 2024, Monopar Therapeutics Inc [MNPR] has been a Buy and the price target has been revised to $50. Analysts at ROTH Capital started covering the stock with ‘”a Buy”‘ outlook in a report released in late January.
Analyzing MNPR Stock Performance
During the last five days, there has been a surge of approximately 471.98%. Over the course of the year, Monopar Therapeutics Inc shares have jumped approximately 1820.05%. Shares of the company reached a 52-week high of $38.50 on 10/24/24 and a 52-week low of $1.54 on 02/07/24. A 50-day SMA is recorded $4.58, while a 200-day SMA reached $3.63. Nevertheless, trading volume fell to 19.49 million shares from 74500.0 shares the previous day.
Support And Resistance Levels for Monopar Therapeutics Inc (MNPR)
In the upper region, resistance lies at 45.82. The next price resistance is at 58.97. RSI (Relative Strength Index) is 93.57 on the 14-day chart, showing overbought technical sentiment. Moving Average Convergence Divergence (MACD) is at 6.97, which suggests the price will increase in the coming days. Percent R is at 17.18%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
